Literature DB >> 29050866

Seizure semiology in leucine-rich glioma-inactivated protein 1 antibody-associated limbic encephalitis.

Chao Chen1, Xiu Wang2, Chao Zhang2, Tao Cui1, Wei-Xiong Shi1, Hong-Zhi Guan3, Hai-Tao Ren3, Xiao-Qiu Shao4.   

Abstract

OBJECTIVE: The objective of this study was to advance the characterization of seizure semiology in leucine-rich glioma-inactivated protein 1 (LGI1) antibody-associated limbic encephalitis (LE).
METHODS: Eighteen patients diagnosed with LGI1 LE were identified. Seizure semiology, demographic features, MRI and fluorodeoxyglucose positron emission tomography (FDG-PET), electroencephalograms, and outcomes following immunotherapy were evaluated.
RESULTS: Patients were divided into the following groups based on seizure semiology: faciobrachial dystonic seizure only (FBDS-only, n=4), epileptic seizure without FBDS (Non-FBDS, n=6), and FBDS plus epileptic seizure (FBDS+, n=8). In the group with Non-FBDS, the majority of patients (5/6) manifested mesial temporal lobe epilepsy (MTLE) like semiology (i.e., fear, epigastric rising, staring, and automatisms) with a frequency of 7±5 times per day and a duration of 15.3±14.3s. In the group with FBDS+, the distinctive symptom was FBDS followed by epileptic events, especially automatisms (7/8), with a frequency of 16±12 times per day and a duration of 13.0±8.0s. In these cases, 67% and 50% of the patients showed abnormalities on MRI and FDG-PET, respectively, and the mesial temporal lobe structures were most often involved. Ictal discharges were observed in 0/4, 6/6, and 8/8 of the patients in the groups with FBDS only, Non-FBDS, and FBDS+, respectively. The temporal lobe was mainly affected. Immunotherapy had favorable therapeutic effects. SIGNIFICANCE: The LGI1 LE should be considered as one disease syndrome with a series of clinical manifestation. Identifying types of unique semiology features will facilitate the early diagnosis and the timely initiation of immunotherapy.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoimmune encephalitis; Faciobrachial dystonic seizure; Mesial temporal lobe epilepsy; Semiology

Mesh:

Substances:

Year:  2017        PMID: 29050866     DOI: 10.1016/j.yebeh.2017.08.011

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  6 in total

1.  Recurrent seizures of autoimmune origin: emerging phenotypes.

Authors:  Mathilde Goudot; Solène Frismand; Lucie Hopes; Antoine Verger; Bastien Joubert; Jérôme Honnorat; Louise Tyvaert
Journal:  J Neurol       Date:  2021-02-27       Impact factor: 4.849

2.  Case Report: Isolated Epileptic Seizures Associated With Anti-LGI1 Antibodies in a 7-Year-Old Girl With Literature Review.

Authors:  Ying Wang; Wei-Hua Zhang; Yuan Wang
Journal:  Front Pediatr       Date:  2022-05-31       Impact factor: 3.569

3.  Clinical and Electroencephalographic Features of the Seizures in Neuronal Surface Antibody-Associated Autoimmune Encephalitis.

Authors:  Yan Wang; Yi Yu; Yaping Hu; Ying Li; Fan Song; Ying Wang
Journal:  Front Neurol       Date:  2020-05-05       Impact factor: 4.003

Review 4.  Diagnostic Value of Structural and Functional Neuroimaging in Autoimmune Epilepsy.

Authors:  Limei Luo; Nian Wei; Jing Wang; Yuemei Luo; Fei Yang; Zucai Xu
Journal:  Contrast Media Mol Imaging       Date:  2020-12-14       Impact factor: 3.161

Review 5.  Anti-LGI1, anti-GABABR, and Anti-CASPR2 encephalitides in Asia: A systematic review.

Authors:  Prinska Ghimire; Ujjwal Prakash Khanal; Bikram Prasad Gajurel; Ragesh Karn; Reema Rajbhandari; Sunanda Paudel; Niraj Gautam; Rajeev Ojha
Journal:  Brain Behav       Date:  2020-08-12       Impact factor: 2.708

6.  Recognition of seizure semiology and semiquantitative FDG-PET analysis of anti-LGI1 encephalitis.

Authors:  Tao-Ran Li; Yu-Di Zhang; Qun Wang; Xiao-Qiu Shao; Rui-Juan Lv
Journal:  CNS Neurosci Ther       Date:  2021-07-22       Impact factor: 5.243

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.